Catalyst Calendar • Endpoint Arena

Catalyst Calendar

Wed, Jul 8, 2026

1 updates

7:30 AM

Lantern Pharma Launches ZetaOmics™ — an Autonomous, Intelligent “Computational Biologist” That Brings Expert-Grade Bioinformatics, Biostatistics & Reasoning to Every Cancer

lanternpharma.com

Tue, Jun 2, 2026

1 updates

8:13 AM

Lantern Pharma Reports HARMONIC™ Data Showing LP-300 Progression-Free Survival Benefit Deepens with Treatment Duration in EGFR Exon 21 L858R Lung Cancer

Trial Results • Phase 2lanternpharma.com

Tue, May 19, 2026

1 updates

7:30 AM

Lantern Pharma Announces Successful Outcome of FDA Type C Meeting Request for HARMONIC™ Phase 2 Trial of LP-300 in Never-Smokers with NSCLC

lanternpharma.com

Fri, May 15, 2026

1 updates

4:01 PM

Lantern Pharma Reports First Quarter 2026 Financial Results and Provides Business Updates

lanternpharma.com

Thu, May 14, 2026

1 updates

4:05 PM

Lantern Pharma Inc. Announces Closing of up to $9.25 Million Registered Direct Offering with Existing Holders and a Single Institutional Investor

lanternpharma.com

Wed, May 13, 2026

1 updates

8:00 AM

Lantern Pharma Inc. Announces up to $9.25 Million Registered Direct Offering with Existing Holders and a Single Institutional Investor

lanternpharma.com

Mon, May 11, 2026

1 updates

4:30 PM

Lantern Pharma to Report First Quarter 2026 Operating & Financial Results on May 15th, 2026

lanternpharma.com

Thu, May 7, 2026

1 updates

9:01 AM

Lantern Pharma Unveils Roadmap for withZeta.ai — Industry-First, Multi-Agentic Co-Scientist Featuring Swarm Intelligence and Computational Biology Toolkit with the Launch of ZetaSwarm™ and ZetaOmics™

lanternpharma.com

Wed, Apr 29, 2026

1 updates

8:50 AM

Lantern Pharma’s predictBBB.ai Evolves Into a Real-Time Large Quantitative Model (LQM) for Precision Molecular Intelligence — Comprehensive Small Molecule Characterization & Development Analytics Available as a Web Service to Drug Developers Globally

lanternpharma.com

Fri, Apr 24, 2026

1 updates

7:50 AM

Lantern Pharma to Debut Public Demonstration of withZeta.ai - A Platform to Conquer Rare Cancers on April 30 Following AACR 2026 Scientific Debut

lanternpharma.com

Mon, Apr 20, 2026

1 updates

8:05 AM

Emerging Data for Lantern Pharma’s Investigational Drug LP-300 Demonstrates 8.3-Month Median Progression-Free Survival in Patients with EGFR L858R Lung Cancer After Targeted Therapy Failure — With No Added Toxicity

lanternpharma.com

Tue, Apr 14, 2026

1 updates

8:31 AM

Lantern Pharma Launches withZeta.ai — the World’s First Multi-Agentic A.I. Co-Scientist for Rare Cancer Drug Discovery & Development — Subscriptions Now Open; Debut Events at Nasdaq MarketSite on 4/16 and at AACR 2026 from 4/17 to 4/22

lanternpharma.com